News
We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.
Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...
Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.
The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...
This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...
The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results